Region Skane

32 trials 13 recruiting Academic / non-commercial

Filter these 32 trials by condition, phase, country and more.

Open in Search →

32 Registered trials

13 Recruiting

14 Completed trials

10 Countries active

68 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 8 Phase II/III: 3 Phase II: 11 Phase III/IV: 2 Phase IV: 7 Phase I (FiH): 1

Oversight events:

1 serious breach across 1 trial

View oversight register →

100%

14 of 14 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Liposarcoma metastatic 1 Polymyalgia rheumatica 1 Systemic lupus erythematosus 1 Anhedonia 1 Dementia 1 Giant cell arteritis 1 Polyarthritis 1 Rheumatoid arthritis 1 Dedifferentiated liposarcoma 1 Neurodegenerative disorder 1 Progressive supranuclear palsy 1 C3 glomerulopathy 1

Top IMPs

2-(6-[18F]FLUORO-PYRIDIN-3-YL)-9H-DIPYRIDO[2,3-B:3',4'-D]PYRROLE 2 BENZYLPENICILLIN SODIUM 2 ADALIMUMAB 1 ADENOSINE 1 ALISKIREN 1 AMOXICILLIN, CLAVULANIC ACID 1 AMPICILLIN 1 ATORVASTATIN 1 CEFOTAXIME 1 CEFTRIAXONE SODIUM 1 CIPROFLOXACIN 1 CLOXACILLIN 1

All trials — page 2

32 total

POLAR BEAR Ended

2022-502887-19-00 Phase III 6 countries POLATUZUMAB VEDOTIN
A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early… Ended

2022-501102-35-00 Phase III 2 countries PEMBROLIZUMAB
Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma - a phase… Ended

2023-509044-96-00 Phase II 2 countries
ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended

2024-514275-18-00 Phase II/III 4 countries IBRUTINIB
Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit… Ended

2024-512243-23-00 Phase III 8 countries IMATINIB
Effect of orlistat on LIVER fat content in obese subjects with NAFLD and High concEntrAtion of pLasma proneurotensin THrough inhibition of n… Ended

2022-500366-10-00 Phase II 1 country ORLISTAT
Lidocaine in Liver Surgery Ended

2023-508173-90-00 Phase II/III 1 country
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Ended

2024-515892-36-00 Phase II 1 country ALISKIREN; ENALAPRIL MALEATE

Showing 25–32 of 32 trials

← All sponsors A–Z